Epidemiology of the Metabolic Syndrome, 2002

American Journal of Managed Care

Volumn 8, Issue 11 SUPPL., 2002, Pages

  Meigs, James B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PIOGLITAZONE; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; DYSLIPIDEMIA; EDUCATION PROGRAM; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; HEALTH SURVEY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; LONGITUDINAL STUDY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; POPULATION RESEARCH; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; AGED; COMPARATIVE STUDY; CONTINUING EDUCATION; FEMALE; HYPERLIPIDEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EDUCATION, CONTINUING; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; UNITED STATES;

EID: 0036719295     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001;24:1936-1940.
2. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
3. Kannel WB, McGee DL. Diabetes and cardiovascular disease: The Framingham Study. JAMA. 1979;241:2035-2038.
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
5. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: Causes and death rates. Diabetologia. 1990;33:538-541.
6. Moss SE, Klein R, Klein BEK. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81:1158-1162.
7. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) 17. A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124 (1 pt 2):136-145.
8. National Diabetes Group. Diabetes in America, 2nd ed. Bethesda, MD: National Institutes of Health; 1995.
9. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22:1125-1136.
10. Harris MI. Ambulatory medical care for diabetes. In: Diabetes in America: Diabetes Data Compiled 1984. Publication 85-1468. Group NDD. Bethesda, MD: National Institutes of Health; 1985.
11. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care. 1998;21:296-309.
12. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
13. Meigs JB. Invited commentary: Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol. 2000;152:908-911.
14. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of diabetes? JAMA. 1990;263:2893-2898.
15. Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis. 1986;6:123-130.
16. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975-980.
17. Salonen JT, Lakka TA, Laaka H-M, Valkonen V-P, Everson SA, Kaplan GA. Hyperinsulinemia is associated with the incidence of hypertension and dyslipidemia in middle-aged men. Diabetes. 1998;47:270-275.
18. Yarnell JW, Patterson CC, Bainton D, Sweetnam PM. Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies. Heart. 1998;79:248-252.
19. Wilson PWF, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-1109.
20. Schmidt MI, Watson RL, Duncan BB, et al. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabolism. 1996;45:699-706.
21. Meigs JB, D'Agostino RB, Wilson PWF, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes. 1997;46:1594-1600.
22. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:1988-1992.
23. Despres J-P, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
24. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation. 1998;98:398-404.
25. Kekalainen P, Sarlund H, Pyorala K, Laakso M. Hyperinsulinemia cluster predicts the development of type 2 diabetes independent of a family history of diabetes. Diabetes Care. 1999;22:86-92.
26. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto, J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation. 1999;100:123-128.
27. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol. 2000;20:538-544.
28. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
29. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia. 2000;43:148-155.
30. Kuusisto J, Lempiainen P, Mykkanen L, Laakso M. Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care. 2001;24:1629-1633.
31. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia. 2001;44:1148-1154.
32. Wilson PWF, D'Agostino RB, Praise H, Meigs JB. The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus [abstract]. Diabetes. 2002;51 (suppl 1):980-P.
33. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442-443.
34. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
35. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
36. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. Diabetes Care. 1998;21:1686-1690.
37. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;36:575-581.
38. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
39. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282:1519-1522.
40. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790-797.
41. Liese AD, Mayer-Davis EJ, Tyroler HA, et al. Familial components of the multiple metabolic syndrome: the ARIC study. Diabetologia. 1997;40:963-970.
42. Xiang AH, Azen SP, Raffel LJ, et al. Evidence for joint genetic control of insulin sensitivity and systolic blood pressure in Hispanic families with a hypertensive proband. Circulation. 2001;103:78-83.
43. Carmelli D, Cardon LR, Fabsitz R. Clustering of hypertension, diabetes, and obesity in adult male twins: same genes or same environments? Am J Hum Genet. 1994;55:566-573.
44. Mayer EJ, Newman B, Austin MA, et al. Genetic and environmental influences on insulin levels and the insulin resistance syndrome: An analysis of women twins. Am J Epidemiol. 1996;143:323-332.
45. Edwards KL, Newman B, Mayer E, Selby JV, Krauss RM, Austin MA. Heritability of factors of the insulin resistance syndrome in women twins. Genet Epidemiol. 1997;14:241-253.
46. Hong Y, Pedersen NL, Brismar K, de Faire U. Genetic and environmental architecture of the features of the insulin-resistance syndrome. Am J Hum Genet. 1997;60:143-152.
47. Poulsen P, Vaag A, Kyvik K, Beck-Nielsen H. Genetic versus environmental aetiology of the metabolic syndrome among male and female twins. Diabetologia. 2001;44:537-543.
48. Mitchell BD, Kammerer CM, Mahaney MC, et al. Genetic analysis of the IRS. Pleiotropic effects of genes influencing insulin levels on lipoprotein and obesity measures. Arterioscl Thromb Vasc Biol. 1996;16:281-288.
49. Kissebah AH, Sonnenberg GE, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA. 2000;97:14478-14483.
50. Duggirala R, Blangero J, Almasy L, et al. A major locus for fasting insulin concentrations and insulin resistance on chromosome 6q with strong pleiotropic effects on obesity-related phenotypes in nondiabetic Mexican Americans. Am J Hum Genet. 2001;68:1149-1164.
51. Arya R, Blangero J, Williams K, et al. Factors of insulin resistance syndrome - related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic Mexican Americans. Diabetes. 2002;51:841-847.
52. Cox NJ. Challenges in identifying genetic variation affecting susceptibility to type 2 diabetes: examples from studies of the calpain-10 gene. Hum Mol Genet. 2001;10:2301-2305.
53. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
54. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
55. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
56. American Diabetes Association and National Institute of Diabetes and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care. 2002;25:742-749.
57. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
58. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 1997;46:433-439.
59. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (troglitazone in the prevention of diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials. 1998;19:217-231.
60. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.
61. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885.
62. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 1997;46(suppl 2):S9-S13.
63. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
64. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.